Embargoed until: 7 a.m. CET on November 3, 2017

Key Financial Data: Q3 2017

Evonik makes further progress in the third quarter

- Adjusted EBITDA rises 11 percent to €639 million
- Outlook for the full year specified: "in the upper half"
- · Integration of Huber's silica business is proceeding

Essen. Evonik increased adjusted EBITDA to €369 million in the third quarter, an increase of 11 percent compared with the third quarter of 2016. This was mainly due to better earnings in the Resource Efficiency and Performance Materials segments. A positive factor was the contribution made by the specialty additives business that Evonik acquired from the US company Air Products at the beginning of the year. Furthermore, the silica business acquired from J. M. Huber at the start of September made a contribution for the first time.

"Having completed the acquisition of Huber's silica business, we reaped the benefit of both acquisitions for the first time," said Executive Board Chairman Christian Kullmann. "The integration of both businesses is proceeding rapidly, and we have already realized initial synergies of around €10 million."

Sales rose to \in 3.56 billion in the third quarter, adjusted net income increased to \in 275 million and adjusted earnings per share improved to \in 0.59. The company's adjusted EBITDA margin was 18 percent, almost one percentage point higher than in the first six months. Free cash flow amounted to \in 485 million in the third quarter, about 70 percent above the prior-year level. Evonik has therefore generated a significantly positive free cash flow since the start of the year.



November 3, 2017

Tim Lange Head of Investor Relations Phone +49 201 177-3150 tim.lange@evonik.com

Evonik Industries AG

Rellinghauser Straße 1–11 45128 Essen Germany Phone +49 201 177–01 Fax +49 201 177–3475 www.evonik.com

Supervisory Board Dr. Werner Müller, Chairman Executive Board Christian Kullmann, Chairman Dr. Harald Schwager, Deputy Chairman Thomas Wessel Ute Wolf

Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474



Outlook specified

Evonik confirmed that it will raise both sales and the operating profit in 2017. Following the positive performance in the third quarter, adjusted EBITDA is now expected to be in the upper half of the \in 2.2 billion to \in 2.4 billion range (2016: \notin 2.165 billion).

Segment performance

Nutrition & Care: Sales increased 3 percent to $\in 1.10$ billion in the third quarter. This was attributable to the consolidation of the business acquired from Air Products and to higher sales volumes. Market conditions for feed additives have improved. Selling prices therefore stabilized in the third quarter but are still considerably lower than in the prior-year quarter. This was the main reason for the decline in adjusted EBITDA to $\in 184$ million in the Nutrition & Care segment.

Resource Efficiency: Sales grew 22 percent to ≤ 1.36 billion in the third quarter. The silica business benefited from strong demand from the tire industry, and sales volumes of oil additives increased thanks to higher demand from the automotive, construction and transportation industries. Consolidation of the operations acquired from Air Products and Huber contributed 14 percentage points of the sales growth. Adjusted EBITDA rose to ≤ 312 million in the Resource Efficiency segment.

Performance Materials: Sales rose 15 percent to \notin 919 million in the third quarter. High demand, especially from the coatings and automotive sectors, combined with continuing tight supply, led to higher selling prices. The adjusted EBITDA of the Performance Materials segment improved to \notin 174 million.



Evonik Group: Excerpt from the income statement

(in € million)	Q3 2017	Q3 2016	Change in %	1-9 2017	1-9 2016	Change in %
Sales	3,556	3,164	12%	10,852	9,527	14%
Adjusted EBITDA	639	578	11%	1,886	1,728	9%
Adjusted EBIT	422	396	7%	1,257	1,191	6%
Adjustments	-30	-15		-198	-74	
Financial result	-71	-55		-152	-183	
Income before income taxes, continuing operations	321	326	-2%	907	934	-3%
Income taxes	-98	-100		-283	-297	
Ergebnis nach Steuern fortgeführter Aktivitäten	223	226	-1%	624	637	-2%
Ergebnis nach Steuern nicht fortgeführter Aktivitäten	2	1		4	1	
Income after taxes	225	227	-1%	628	638	-2%
thereof attributable to non-controlling interests	5	4		14	10	
Net Income	220	223	-1%	614	628	-2%
Adjusted net income	275	247	11%	825	748	10%

Segment performance

	Sales			Adjusted EBITDA		
	Q3 2017 € million	Q3 2016 € million	Change in %	Q3 2017 € million	Q3 2016 € million	Change in %
Nutrition & Care	1,101	1,066	3%	184	239	-23%
Resource Efficiency	1,359	1,117	22%	312	262	19%
Performance Materials	919	797	15%	174	104	67%
Services	172	173	-1%	46	50	-8%
Other operations	5	11		-77	-77	
Group	3,556	3,164	12%	639	578	11%

	Sales			Adjusted EBITDA			
	1−9 2017 € million	1−9 2016 € million	Change in %	1−9 2017 € million	1-9 2016 € million	Change in %	
Nutrition & Care	3,376	3,223	5%	569	796	-29%	
Resource Efficiency	4,118	3,392	21%	941	788	19%	
Performance Materials	2,807	2,399	17%	502	273	84%	
Services	538	503	7%	122	119	3%	
Other operations	13	10		-248	-248		
Group	10,852	9,527	14%	1,886	1,728	9%	

Employees by segment

	30.09.2017	31.12.2016
Nutrition & Care	8,549	7,594
Resource Efficiency	9,142	8,928
Performance Materials	4,406	4,393
Services	12,705	12,892
Other operations	622	544
Evonik	35,424	34,351



Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016, the enterprise generated sales of around $\in 12.7$ billion and an operating profit (adjusted EBITDA) of about $\notin 2.165$ billion.

Disclaimer

In so far as forecasts or expectations are expressed in this investor relations news or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.